Arbutus Biopharma

Company Overview

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company that draws on its extensive expertise in virology to identify and develop innovative therapeutics with unique mechanisms of action. These therapies are aimed at potentially offering a functional cure for individuals with chronic hepatitis B virus (cHBV). The company believes that successfully achieving a functional cure involves three primary strategies: suppressing HBV DNA, reducing surface antigen levels, and enhancing HBV-specific immune responses.

The company’s pipeline consists of internally developed proprietary compounds, including imdusiran (AB-729), an RNAi therapeutic, and AB-101, an oral PD-L1 inhibitor. Notably, imdusiran is the sole RNAi therapeutic that has shown promising clinical data indicating an impact on both reducing surface antigen levels and reactivating the HBV-specific immune response. Presently, imdusiran is undergoing evaluation in two Phase 2a combination clinical trials, while AB-101 is being assessed in a Phase 1a/1b clinical trial.

Moreover, the company is exploring potential oncology applications for its internal PD-L1 portfolio.

Financial Highlights (FY 2024)